Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Slideshows|April 29, 2020
Prevention of Covert COVID Iatrogenesis
Author(s)Harold J. Bursztajn, MD
In a time of panic, despair, and demoralization, art continues to inspire the author's reflections as it has over the last 40 years. Here, he shares some images that he finds inspirational and helpful. Even in winter there is hope.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
4
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
5